HT
CRSP icon

Headlands Technologies’s CRISPR Therapeutics CRSP Stock Holding History

Headlands Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$827K Buy
+17,393
New +$917K 0.09% 251
2025
Q3 		– Sell
-8,092
Closed -$394K – 752
2025
Q2 		$394K Buy
+8,092
New +$313K 0.05% 357
2024
Q3 		– Sell
-3,440
Closed -$186K – 1248
2024
Q2 		$186K Buy
+3,440
New +$199K 0.02% 495
2023
Q4 		– Sell
-754
Closed -$34.2K – 1000
2023
Q3 		$34.2K Buy
+754
New +$38.9K 0.02% 505

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Headlands Technologies's CRSP Position: Q1 2026 in Review

Headlands Technologies opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 17,393 shares worth $827K. The stake represents 0.09% of the portfolio and ranks #251 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in CRSP as recently as Q2 2025.

Headlands Technologies first reported a position in CRSP in Q3 2023 and has held it in 4 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Headlands Technologies held 17,393 shares of CRISPR Therapeutics worth $827K as of Q1 2026.
  • CRISPR Therapeutics was a new Headlands Technologies position in Q1 2026.
  • CRISPR Therapeutics made up 0.09% of Headlands Technologies's portfolio in Q1 2026, its #251 holding.
  • Headlands Technologies first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 4 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.